SEARCH

SEARCH BY CITATION

References

  • Adolfsson R., Gottfries C. G., Roos B. E. and Winblad B. (1979) Post-mortem distribution of dopamine and homovanillic acid in human brain, variations related to age, and a review of the literature. J. Neural Transm. 45, 81105.
  • Allard P. and Marcusson J. O. (1989) Age-correlated loss of dopamine uptake sites labelled with [3H]GBR-12935 in human putamen. Neurobiol. Aging 10, 661664.
  • Bannon M. J., Poosch M. S., Xia Y., Goebel D. J., Cassin B. and Kapatos G. (1992) Dopamine transporter mRNA content in human substantia nigra decreases precipitously with age. Proc. Natl Acad. Sci. USA 89, 70957099.
  • Bird E. D. and Iversen L. L. (1974) Huntington's chorea: post-mortem measurement of glutamic acid decarboxylase, choline acetyl-transferase and dopamine in basal ganglia. Brain 97, 457472.
  • Black I. B. and Green S. C. (1975) Postmortem changes in brain catecholamine enzymes. Arch. Neurol. 32, 4749.
  • Chen E. Y., Kallwitz E., Leff S. E., Cochran E. J., Mufson E. J., Kordower J. H. and Mandel R. J. (2000) Age-related decreases in GTP-cyclohydrolase-I immunoreactive neurons in the monkey and human substantia nigra. J. Comp. Neurol. 426, 534548.
  • Côté L. J. and Kremzner L. T. (1983) Biochemical changes in normal aging in human brain. Adv. Neurol. 38, 1930.
  • DiChiara G. (1995) The role of dopamine in drug abuse viewed from the perspective of its role in motivation. Drug Alcohol Depend. 38, 95137.
  • Dumas S., Le Hir H., Bodeau-Péan S., Hirsch E., Thermes C. and Mallet J. (1996) New species of human tyrosine hydroxylase mRNA are produced in variable amounts in adrenal medulla and are overexpressed in progressive supranuclear palsy. J. Neurochem. 67, 1925.
  • Ehringer H. and Hornykiewicz O. (1960) Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin. Wochenschr. 38, 12361239.
  • Erickson J. D., Schafer M. K.-H., Bonner T. I., Eiden L. E. and Weihe E. (1996) Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular transporter. Proc. Natl Acad. Sci. USA 93, 51665171.
  • Erickson S. L., Akil M., Levey A. I. and Lewis D. A. (1998) Postnatal development of tyrosine hydroxylase- and dopamine transporter-immunoreactive axons in monkey rostral entorhinal cortex. Cereb. Cortex 8, 415427.
  • Fearnley J. M. and Lees A. J. (1991) Aging and Parkinson's disease: substantia nigra regional selectivity. Brain 114, 22832301.
  • Fitzpatrick P. F. (1999) Tetrahydropterin-dependent amino acid hydroxylases. Annu. Rev. Biochem. 68, 355381.
  • Floyd R. A. (1999) Antioxidants, oxidative stress, and degenerative neurological disorders. Proc. Soc. Exp. Biol. Med. 222, 236245.
  • Frey K. A., Koeppe R. A., Kilbourn M. R., Vander Borght T. M., Albin R. L., Gilman S. and Kuhl D. E. (1996) Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann. Neurol. 40, 873884.
  • Frey K. A., Koeppe R. A. and Kilbourn M. R. (2001) Imaging the vesicular monoamine transporter. Adv. Neurol. 86, 237247.
  • Furukawa Y. and Kish S. J. (1998) Influence of development and aging on brain biopterin: implications for dopa-responsive dystonia onset. Neurology 51, 632634.
  • Gaspar P., Javoy-Agid F., Ploska A. and Agid Y. (1980) Regional distribution of neurotransmitter synthesizing enzymes in the basal ganglia of human brain. J. Neurochem. 34, 278283.
  • Girault J. A., Raisman-Vozari R., Agid Y. and Greengard P. (1989) Striatal phosphoproteins in Parkinson disease and progressive supranuclear palsy. Proc. Natl Acad. Sci. USA 86, 24932497.
  • Giros B., El Mestikawy S., Godinot N., Zheng K., Han H., Yang-Feng T. and Caron M. G. (1992) Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol. Pharmacol. 42, 383390.
  • Haug H. and Eggers R. (1991) Morphometry of the human cortex cerebri and corpus striatum during aging. Neurobiol. Aging 12, 336338.
  • Haycock J. W. (1989) Quantitation of tyrosine hydroxylase protein levels: spot immunolabeling with an affinity-purified antibody. Anal. Biochem. 181, 259266.
  • Haycock J. W. (1991) Four forms of tyrosine hydroxylase are present in human adrenal medulla. J. Neurochem. 56, 21392142.
  • Haycock J. W. (1993a) Multiple forms of tyrosine hydroxylase in human neuroblastoma cells: quantitation with isoform-specific antibodies. J. Neurochem. 60, 493502.
  • Haycock J. W. (1993b) Polyvinylpyrrolidone as a blocking agent in immunochemical studies. Anal. Biochem. 208, 397399.
  • Haycock J. W. (2002) Species differences in the expression of multiple tyrosine hydroxylase protein isoforms. J. Neurochem. 81, 947953.
  • Hirai S. (1968) Ageing of the substantia nigra. Adv. Neurol. Sci. 12, 845849.
  • Hyland K., Surtees R. A. H., Rodeck C. and Clayton P. T. (1992) Aromatic 1-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a new inborn error of neurotransmitter amine synthesis. Neurology 42, 19801988.
  • Ichinose H., Kurosawa Y., Titani K., Fujita K. and Nagatsu T. (1989) Isolation and characterization of a cDNA clone encoding human aromatic 1-amino acid decarboxylase. Biochem. Biophys. Res. Commun. 164, 10241030.
  • Irwin I., DeLanney L. E., McNeill T., Chan P., Forno L. S., Murphy G. M. Jr, Di Monte D. A., Sandy M. S. and Langston J. W. (1994) Aging and the nigrostriatal dopamine system: a non-human primate study. Neurodegeneration 3, 251265.
  • Kalaria R. N., Fiedler C., Hunsaker J. C. III and Sparks D. L. (1993) Synaptic neurochemistry of human striatum during development: changes in sudden infant death syndrome. J. Neurochem. 60, 20982105.
  • Kish S. J., Shannak K. and Hornykiewicz O. (1988) Uneven pattern of dopamine loss in striatum of patients with idiopathic Parkinson's disease: pathophysiologic and clinical implications. New Eng. J. Med. 318, 876880.
  • Kish S. J., Shannak K., Rajput A., Deck J. H. N. and Hornykiewicz O. (1992) Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease. J. Neurochem. 58, 642648.
  • Kish S. J., Zhong X.-H., Hornykiewicz O. and Haycock J. W. (1995) Striatal 3,4-dihydroxyphenylalanine decarboxylase in aging: disparity between postmortem and positron emission tomography studies? Ann. Neurol. 5, 260264.
  • Kubis N., Faucheux B. A., Ransmayr G. et al. (2000) Preservation of midbrain catecholaminergic neurons in very old human subjects. Brain 123, 366373.
  • Lewis D. A., Melchitsky D. S. and Haycock J. W. (1993) Four isoforms of tyrosine hydroxylase are expressed in human brain. Neuroscience 54, 477492.
  • Little K. Y., Kirkman J. A., Carroll F. I., Clark T. B. and Duncan G. E. (1993) Cocaine use increases [3H]WIN 35428 binding sites in human striatum. Brain Res. 628, 1725.
  • Little K. Y., Carroll F. I. and Butts J. D. (1998) Striatal [125I]RTI-55 binding sites in cocaine-abusing humans. Prog. Neuropsychopharmacol. Biol. Psychiat. 22, 455466.
  • Lloyd K. G. and Hornykiewicz O. (1972) Occurrence and distribution of aromatic 1-amino acid (L-DOPA) decarboxylase in the human brain. J. Neurochem. 26, 6576.
  • Mackay A. V. P., Yates C. M., Wright A., Hamilton P. and Davies P. (1978) Regional distribution of monoamines and their metabolites in the human brain. J. Neurochem. 30, 841848.
  • Mann D. M. A. and Yates P. O. (1979) The effects of aging on the pigmented nerve cells of the human locus coeruleus and substantia nigra. Acta Neuropath. 47, 9397.
  • McGeer E. G., Gibson S., Wada J. A. and McGeer P. L. (1967) Distribution of tyrosine hydroxylase activity in adult and developing brain. Can. J. Biochem. 45, 19431952.
  • McGeer E. G. and McGeer P. L. (1975) Age changes in the human for some enzymes asssociated with metabolism of catecholamines, GABA, and acetylcholine, in Neurobiology of Ageing (Ordy, J. M. and Brizee, K. R., eds), pp. 287305. Plenum Press, New York.
  • McGeer E. and McGeer P. L. (1976a) Neurotransmitter metabolism in the aging brain. In: Neurobiology of Aging (Terry, R. D. and Gershon, S., eds), pp. 389403. Raven Press, New York.
  • McGeer P. L. and McGeer E. G. (1976b) Enzymes associated with the metabolism of catecholamines, acetylcholine, and GABA in human controls and patients with Parkinson's disease and Huntington's chorea. J. Neurochem. 26, 6576.
  • McGeer P. L., McGeer E. G. and Suzuki J. S. (1977) Aging and extrapyramidal function. Arch. Neurol. 34, 3335.
  • Mozley P. D., Acton P. D., Barraclough E. D., Plossl K., Gur R. C., Alavi A., Mathur A., Saffer J. and Kung H. F. (1999) Effects of age on dopamine transporters in healthy humans. J. Nucl. Med. 40, 18121817.
  • Oakman S., Zhang L., Maddox R. and Little K. Y. (2000) Cocaine effects on striatal dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) protein in humans. Biol. Psychiat. 47, 130S.
  • Ordway G. A., Smith K. S. and Haycock J. W. (1994) Elevated tyrosine hydroxylase in the locus coeruleus of suicide victims. J. Neurochem. 62, 680685.
  • Pirker W., Asenbaum S., Hauk M., Kandlhofer S., Tauscher J., Willeit M., Neumeister A., Praschak-Rieder N., Angelberger P. and Brucke T. (2000) Imaging serotonin and dopamine transporters with 123I-beta-CIT SPECT: binding kinetics and effects of normal aging. J. Nucl. Med. 41, 3644.
  • Rajput A. H., Gibb W. R. G., Zhong X.-H., Shannak K. S., Kish S. J., Chang L. G. and Hornykiewicz O. (1994) DOPA responsive dystonia: pathological and biochemical observations in a case. Ann. Neurol. 35, 396402.
  • Rehavi M., Goldin M., Roz N. and Weizman A. (1998) Regulation of rat brain vesicular monoamine transporter by chronic treatment with ovarian hormones. Brain Res. Mol. Brain Res. 57, 3137.
  • Robinson D. S., Sourkes T. L., Nies A., Harris L. S., Spector S., Bartlett D. L. and Kaye I. S. (1977) Monoamine metabolism in human brain. Arch. Gen. Psychiat. 34, 8992.
  • Romero-Ramos M., Rodriguez-Gomez J. A., Venero J. L., Cano J. and Machado A. (1997) Chronic inhibition of the high-affinity dopamine uptake system increases oxidative damage to proteins in the aged rat substantia nigra. Free Radic. Biol. Med. 23, 17.
  • Rosenberg D. R. and Lewis D. A. (1994) Changes in the dopaminergic innervation of monkey prefrontal cortex during late postnatal development: a tyrosine hydroxylase immunohistochemical study. Biol. Psychiat. 36, 272277.
  • Rosenberg D. R. and Lewis D. A. (1995) Postnatal maturation of the dopaminergic innervation of monkey prefrontal and motor cortices: a tyrosine hydroxylase immunohistochemical analysis. J. Comp. Neurol. 358, 383400.
  • Sailaja K. and Gopinath G. (1994) Developing substantia nigra in human: a qualitative study. Dev. Neurosci. 16, 4452.
  • Scherman D., Desnos C., Darchen F., Pollak P., Javoy-Agid F. and Agid Y. (1989) Striatal dopamine deficiency in Parkinson's disease: role of aging. Ann. Neurol. 26, 551557.
  • Seeman P. and Lee T. (1975) Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188, 12171219.
  • Smith J. A., Hurrell J. G. R. and Leach S. J. (1978) Elimination of nonspecific adsorption of serum products by sepharose-bound antigens. Anal. Biochem. 87, 299305.
  • Smith P. K., Krohn R. I., Hemanson G. T. et al. (1985) Measurement of protein using bichinchoninic acid. Anal. Biochem. 150, 7685.
  • Staley J. K., Hearn W. L., Ruttenber A. J., Wetli C. V. and Mash D. C. (1994) High affinity cocaine recognition sites on the dopamine transporter are elevated in fatal cocaine overdose victims. J. Pharmacol. Exp. Ther. 271, 16781685.
  • Staley J. K., Segal D. M., Heilman C. J., Levey A. I. and Mash D. C. (1995) Quantification of dopamine transporter proteins in cocaine fatalities using immunological approaches. Soc. Neurosci. Abstract 21, 721.
  • Tennyson V. M., Barrett R. E., Cohen G., Côté L., Heikkila R. and Mytilineou C. (1972) The developing neostriatum of the rabbit: correlation of fluorescence histochemistry, electron microscopy, endogenous dopamine levels, and [3H]dopamine uptake. Brain Res. 46, 251285.
  • Thiessen B., Rajput A. H. and Desai H. (1990) Age, environments, and the number of substantia nigra neurons. Adv. Neurol. 38, 201205.
  • Tissingh G., Bergmans P., Booij J., Winogrodzka A., Stoof J. C., Wolters E. C. and Van Royen E. A. (1997) [123I]beta-CIT single-photon emission tomography in Parkinson's disease reveals a smaller decline in dopamine transporters with age than in controls. Eur. J. Nucl. Med. 24, 11711174.
  • Tsang V. C. W. and Wilkins P. P. (1991) Optimum dissociating conditions for immunoaffinity and preferential isolation of antibodies with high specific activity. J. Immunol. Meth. 138, 291299.
  • Vander Borght T., Kilbourn M., Desmond T., Kuhl D. and Frey K. (1995) The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur. J. Pharmacol. 294, 577583.
  • Vilpoux C., Leroux-Nicollet I., Naudon L., Raisman-Vozari R. and Costentin J. (2000) Reserpine or chronic paroxetine treatments do not modify the vesicular monoamine transporter 2 expression in serotonin-containing regions of the rat brain. Neuropharmacology 39, 10751082.
  • Volkow N. D., Fowler J. S., Wang G. J., Logan J., Schlyer D., MacGregor R., Hitzemann R. and Wolf A. P. (1994) Decreased dopamine transporters with age in health human subjects. Ann. Neurol. 36, 237239.
  • Volkow N. D., Ding Y. S., Fowler J. S., Wang G. J., Logan J., Gatley S. J., Hitzemann R., Smith G., Fields S. D. and Gur R. (1996) Dopamine transporters decrease with age. J. Nucl. Med. 37, 554559.
  • Volkow N. D., Wang G. J., Fowler J. S. et al. (1998) Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging. Ann. Neurol. 44, 143147.
  • Wilson J. M. and Kish S. J. (1996) The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J. Neurosci. 16, 35073510.
  • Wilson J. M., Nobrega J. N., Carroll M. E., Niznik H. B., Shannak K., Lac S. T., Pristupa Z. B., Dixon L. M. and Kish S. J. (1994) Heterogeneous subregional binding patterns of 3H-WIN 35,428 and 3H-GBR 12,935 are differentially regulated by chronic cocaine self-administration. J. Neurosci. 14, 29662979.
  • Wilson J. M., Levey A. I., Bergeron C. et al. (1996a) Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann. Neurol. 40, 428439.
  • Wilson J. M., Levey A. I., Rajput A., Ang L., Guttman M., Shannak K., Niznik H. B., Hornykiewicz O., Pifl C. and Kish S. J. (1996b) Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 47, 718726.
  • Wolf M. E., LeWitt P. A., Bannon M. J., Dragovic L. J. and Kapatos G. (1991) Effect of aging on tyrosine hydroxylase protein content and the relative number of dopamine nerve terminals in human caudate. J. Neurochem. 56, 11911200.
  • Yoshida Y. I., Eda S. and Masada M. (2000) Alterations of tetrahydrobiopterin biosynthesis and pteridine levels in mouse tissues during growth and aging. Brain Dev. 22, S45S49.
  • Zelnik N., Angel I., Paul S. M. and Kleinman J. E. (1986) Decreased density of human striatal dopamine uptake sites with age. Eur. J. Pharmacol. 126, 175176.
  • Zhong X.-H., Haycock J. W., Robitaille Y., Fratkin J., Kopin A., Shannak K., Hornykiewicz O. and Kish S. J. (1995) Striatal tyrosine hydroxylase and dopa decarboxylase protein in dominantly-inherited olivopontocerebellar atrophy and idiopathic Parkinson's disease. Mov. Disorders 10, 1017.